ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas W. Rice
Thomas J. Kirby
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rice, T. W.
Right arrow Articles by Budd, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rice, T. W.
Right arrow Articles by Budd, G. T.

Ann Thorac Surg 1995;60:586-591
© 1995 The Society of Thoracic Surgeons

Original Articles: General Thoracic

Accelerated Induction Therapy and Resection for Poor Prognosis Stage III Non–Small Cell Lung Cancer

Thomas W. Rice, MD, David J. Adelstein, MD, Anuradha Koka, MD, Melvin Tefft, MD, Thomas J. Kirby, MD, Marjorie A. Van Kirk, RN, Marie E. Taylor, MD, Thomas E. Olencki, DO, David Peereboom, MD, G. Thomas Budd, MD

Departments of Thoracic and Cardiovascular Surgery, Hematology and Medical Oncology, and Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio

Background. Induction therapy and resection may improve the survival of patients with poor prognosis stage III non–small cell lung cancer, at the cost of significant treatment prolongation. The purpose of this study was to assess toxicity, response, and survival of an accelerated induction regimen and resection in poor prognosis stage III non–small cell lung cancer.

Methods. Forty-two surgically staged patients with poor prognosis stage III non–small cell lung cancer received 11 days of induction treatment consisting of 96 hours of continuous chemotherapy infusions of cisplatin (20 mg • m-2 • day-2), 5 fluorouracil (1,000 mg • m-2 • day-2), and etoposide (75 mg • m-2 • day-2) concurrent with accelerated fractionation radiation therapy (1.5 Gy twice a day, to a dose of 27 Gy). Induction was followed in 4 weeks by resection. Postoperatively, a second course of continuous chemotherapy and concurrent accelerated fractionation radiation therapy (postoperative dose 13 to 36 Gy) was given.

Results. Despite some degree of induction toxicity in all patients there was only one induction death (2.4%). A clinical partial response was seen in 24 patients (57%). Thirty-six patients (86%) underwent thoracotomy, and resection was possible in 33 (79%). Pathologic downstaging was seen in 17 patients (40%), and 2 patients (5%) had no residual carcinoma at operation. There were 11 postoperative complications (31%) and 4 postoperative deaths (11%). Thirteen patients (31%) are alive and disease-free, 24 (57%) have persistent disease or have recurred (15 distant, 5 locoregional, 4 both), and 9 patients are alive with disease. The median survival is 21 months and the 2-year Kaplan-Meier survival is 43%, with no differences identified between stages IIIA and IIIB patients (p= 0.63).

Conclusions. We conclude that accelerated induction therapy and resection in poor prognosis stage III non–small cell lung cancer (1) is toxic, with a 12% treatment mortality; (2) is effective with a 79% resection rate and 40% pathologic downstaging rate; (3) provides excellent local control; (4) may prolong survival; and (5) is of value in stage IIIB as well as stage IIIA patients.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al.
Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy
Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. Doddoli, F. Barlesi, D. Trousse, S. Robitail, S. Yena, P. Astoul, R. Giudicelli, P. Fuentes, and P. Thomas
One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 416 - 425.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. K. Ferguson
Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1935 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. M. DeCamp, T. W. Rice, D. J. Adelstein, M. A. Chidel, L. A. Rybicki, S. C. Murthy, and E. H. Blackstone
Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 17 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Stamatis, D. Djuric, W. Eberhardt, C. Pottken, G. Zaboura, S. Fechner, and T. Fujimoto
Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients
Eur. J. Cardiothorac. Surg., August 1, 2002; 22(2): 292 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.F. Vansteenkiste
Imaging in lung cancer: positron emission tomography scan
Eur. Respir. J., February 1, 2002; 19(35_suppl): 49S - 60s.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
N. Novoa, G. Varela, and M.F. Jimenez
Morbidity after surgery for non-small cell lung carcinoma is not related to neoadjuvant chemotherapy
Eur. J. Cardiothorac. Surg., October 1, 2001; 20(4): 700 - 704.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Doddoli, P. Thomas, X. Thirion, Y. Seree, R. Giudicelli, and P. Fuentes
Postoperative complications in relation with induction therapy for lung cancer
Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 385 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.F. Vansteenkiste and S.G. Stroobants
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
Eur. Respir. J., April 1, 2001; 17(4): 802 - 820.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. W. Rice, D. J. Adelstein, J. P. Ciezki, M. E. Becker, L. A. Rybicki, C. F. Farver, M. A. Larto, and E. H. Blackstone
Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer
Ann. Thorac. Surg., December 1, 1998; 66(6): 1909 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts
Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review
Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. D. Lee and R. J. Ginsberg
Lung Cancer Staging: The Value of Ipsilateral Scalene Lymph Node Biopsy Performed at Mediastinoscopy
Ann. Thorac. Surg., August 1, 1996; 62(2): 338 - 341.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1995 by The Society of Thoracic Surgeons.